Certain blood disorders can lead to Raynaud's symptoms and other effects. A rare anemia called cold agglutinin disease is among them; it has been associated with chronic lymphocytic leukemia.

Recordati is acquiring Sanofi’s Enjaymo, the only approved drug for the rare blood disorder cold agglutinin disease. Achieving sales milestones could bring the deal’s value to more than $1 ...

Sanofi has won FDA approval for its sutimlimab for cold agglutinin disease (CAD) at the second time of asking, becoming the first approved therapy for the rare blood disorder in the US.

The French pharma also noted that Bioverativ has a pipeline including a phase 3 drug for cold agglutinin disease, and early stage research collaborations in haemophilia, and other rare blood ...

The Business Research Company Enjaymo Global Market Report 2025 – Market Size, Trends, And Global Forecast 2025-2034 The enjaymo ma ...